EP. 1: Impact of Driver Mutations in NSCLC
EP. 2: Off-Label Crizotinib for the Treatment of METex14-Mutated NSCLC
EP. 3: FDA Priority Review of Capmatinib for METex14-Mutated NSCLC
EP. 4: The Availability of MET Inhibitors for NSCLC
EP. 5: Benefit of Alpelisib/Fulvestrant Combo in HR+/HER- Breast Cancer Confirmed With Biomarker Analysis
Combination of alpelisib and fulvestrant shows clinical benefit in patients with hormone receptor–positive, HER2-negative advanced breast cancer regardless of gene mutation status, according to a retrospective biomarker analysis.
2 Clarke Drive Cranbury, NJ 08512